TR200103418T2 - Melatoninin tedavi edici kullanımı. - Google Patents

Melatoninin tedavi edici kullanımı.

Info

Publication number
TR200103418T2
TR200103418T2 TR2001/03418T TR200103418T TR200103418T2 TR 200103418 T2 TR200103418 T2 TR 200103418T2 TR 2001/03418 T TR2001/03418 T TR 2001/03418T TR 200103418 T TR200103418 T TR 200103418T TR 200103418 T2 TR200103418 T2 TR 200103418T2
Authority
TR
Turkey
Prior art keywords
symptoms
patient
melatonin
neuroleptic
composition
Prior art date
Application number
TR2001/03418T
Other languages
English (en)
Inventor
Z�Sapel Nava
Laudon Moshe
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of TR200103418T2 publication Critical patent/TR200103418T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus bir yönüyle, en azindan bir tasiyici, sulandirici veya etkiyi artiran bilesime ek olarak bu tedaviye ihtiyaç duyan bir hastada nöroleptik etki olusturacak miktarda en azindan bir nöroleptik bilesimden ve hastada gelisen TD belirtilerini iyilestiren veya önleyen miktarda melatoninden olusan farmakolojik bir formülasyon saglar. Baska bir yönüyle, bulus bir hastada TD belirtilerinin önlenmesi ve iyilestirilmeisi için gereken ilacin üretiminde melatoninin kullanimini saglar. Ilaç tercihen asagidaki ilave (a) ve (b) ögelerinden en azindan birini içeren farmakolojik formülasyonun seklini alir: (a) en azindan bir tasiyici, sulandirici veya etki artirici. (b) bu tedaviye ihtiyaç duyan bir hastada sinir sistemi üzerine etki olusturacak miktarda en azindan bir nöroleptik bilesim. Ayrica bulusa uygun olarak, bir hastada TD belirtilerini önlemek ve tedavi etmek için bir yöntem, bu tip belirtileri gösteren veya aksi halde bu tip belirtileri gelistirmeye meyilli hastada TD belirtilerini
TR2001/03418T 1999-05-27 2000-05-24 Melatoninin tedavi edici kullanımı. TR200103418T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13017199A IL130171A (en) 1999-05-27 1999-05-27 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines

Publications (1)

Publication Number Publication Date
TR200103418T2 true TR200103418T2 (tr) 2004-12-21

Family

ID=11072852

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03418T TR200103418T2 (tr) 1999-05-27 2000-05-24 Melatoninin tedavi edici kullanımı.

Country Status (30)

Country Link
US (1) US6566389B1 (tr)
EP (1) EP1183024A4 (tr)
JP (1) JP2003500446A (tr)
KR (1) KR20020015329A (tr)
CN (1) CN1176652C (tr)
AR (1) AR036321A1 (tr)
AU (1) AU775520B2 (tr)
BG (1) BG106234A (tr)
BR (1) BR0017329A (tr)
CA (1) CA2374129A1 (tr)
CZ (1) CZ20014190A3 (tr)
EA (1) EA004057B1 (tr)
EE (1) EE200100623A (tr)
HK (2) HK1046089A1 (tr)
HU (1) HUP0201405A3 (tr)
IL (1) IL130171A (tr)
IS (1) IS6172A (tr)
MX (1) MXPA01012040A (tr)
NO (1) NO319421B1 (tr)
NZ (1) NZ515866A (tr)
PE (1) PE20010129A1 (tr)
PL (1) PL351885A1 (tr)
SK (1) SK16402001A3 (tr)
TN (1) TNSN00117A1 (tr)
TR (1) TR200103418T2 (tr)
TW (1) TWI236906B (tr)
UA (1) UA71968C2 (tr)
UY (1) UY26171A1 (tr)
WO (1) WO2000072843A1 (tr)
ZA (1) ZA200110436B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP1715742A4 (en) * 2004-02-20 2009-06-17 Lifescape Biosciences Inc COMPOSITIONS AND METHODS FOR SLEEPING
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
US7494674B2 (en) 2006-09-22 2009-02-24 Lapointe Andrew T Nutraceutical with tart cherries and method of treatment therewith
EP2124907B1 (en) 2007-03-19 2018-05-30 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691324A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production

Also Published As

Publication number Publication date
WO2000072843A1 (en) 2000-12-07
AU4775600A (en) 2000-12-18
BR0017329A (pt) 2003-07-29
CA2374129A1 (en) 2000-12-07
EE200100623A (et) 2003-02-17
CZ20014190A3 (cs) 2002-05-15
UY26171A1 (es) 2000-12-29
EP1183024A1 (en) 2002-03-06
TNSN00117A1 (fr) 2005-11-10
EA200101240A1 (ru) 2002-06-27
NO20015738L (no) 2002-01-25
PE20010129A1 (es) 2001-04-27
US6566389B1 (en) 2003-05-20
EA004057B1 (ru) 2003-12-25
CN1352556A (zh) 2002-06-05
EP1183024A4 (en) 2007-02-28
UA71968C2 (en) 2005-01-17
HK1046089A1 (zh) 2002-12-27
BG106234A (bg) 2002-08-30
MXPA01012040A (es) 2003-09-04
NZ515866A (en) 2003-05-30
HUP0201405A3 (en) 2003-11-28
IL130171A (en) 2004-06-01
IS6172A (is) 2001-11-22
HUP0201405A2 (en) 2002-08-28
AR036321A1 (es) 2004-09-01
HK1047048B (zh) 2005-05-27
IL130171A0 (en) 2000-06-01
CN1176652C (zh) 2004-11-24
NO319421B1 (no) 2005-08-08
PL351885A1 (en) 2003-06-30
TWI236906B (en) 2005-08-01
HK1047048A1 (en) 2003-02-07
SK16402001A3 (sk) 2002-04-04
ZA200110436B (en) 2004-03-31
AU775520B2 (en) 2004-08-05
KR20020015329A (ko) 2002-02-27
NO20015738D0 (no) 2001-11-26
JP2003500446A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
ATE320800T1 (de) Synergistische kombination von roflumilast und salmeterol
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
ATE359806T1 (de) Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
SE9901272D0 (sv) New improved formulation
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.